Rhamnan sulfate an agent that might protect microcirculation, vascular endothelium and glycocalyx

#1

Aosa seaweed (Monostroma nitidum) contains rhamnan sulfate, a sulfated polysaccharide that show potential to support microcirculation by protecting vascular endothelium, reducing inflammation, and inhibiting coagulation factors. This is a food and a substance previously unknown to me. it was brought to my attention when I researched ways to protect microcirculation, vascular endothelium and the glycocalyx. I find almost only research from japan. And very limited human research. Input or experiences from the forum is appreciated.

Capillary aging involves endothelial dysfunction, inflammation, and glycocalyx degradation, which rhamnan sulfate counters by reducing NF-κB activity, enhancing barrier function, and limiting hyperpermeability in hyperglycemic models linked to accelerated vascular aging, Rhamnan sulfate mitigates hippocampal atrophy and TNF-α-driven inflammation, suggesting potential slowdown of age-related capillary decline through improved endothelial stability. Human evidence remains preclinical or indirect

I have previously not known much about the endothelial glycocalyx but Ai explains that it is a gel-like extracellular matrix coating the luminal surface of blood vessel endothelial cells, composed of proteoglycans and glycoproteins.​ endothelial glycocalyx integrity, the lining of blood vessels crucial for microcirculatory function and regulating permeability. It ameliorates lipid metabolism abnormalities, suppresses vascular inflammation, and inhibits macrophage infiltration, directly benefiting capillary health in atherosclerosis-prone models.

It regulates vascular permeability by acting as a selective barrier, preventing excessive fluid and protein leakage while allowing nutrient exchange. The glycocalyx also senses shear stress for mechanotransduction, modulates inflammation by limiting leukocyte adhesion, inhibits thrombosis, and binds signaling molecules like VEGF.​

Degradation occurs in aging, diabetes, and inflammation via enzymes like heparanase, leading to endothelial dysfunction, hyperpermeability, and capillary rarefaction—key factors in vascular aging relevant to rhamnan sulfate protection.

Since I focus more and more on my microcirculation and the health of my capillaries and glycocalyx. I find Aosa seaweed, Monostroma nitidum containing rhamnan sulfate is an interesting food to explore.

1 Like
#2

Most of us in this community are familiar with the usual vascular toolkit — pycnogenol, L-citrulline, omega-3, beetroot. But over the past couple of years, a more unusual compound has been quietly gaining attention among people focused on capillary health and endothelial function: rhamnan sulfate (RS), a sulphated polysaccharide extracted from the green seaweed Monostroma nitidum, eaten for centuries in Japan.

What makes RS interesting is its mechanism. Rather than stimulating the endothelium to produce more nitric oxide — which is what most vascular compounds do — RS appears to work at the surface layer of the blood vessel itself. Its molecular structure closely resembles heparan sulfate, the primary building block of the endothelial glycocalyx: the gel-like coating on the inner wall of your capillaries that controls what gets in, prevents LDL from penetrating the vessel wall, and acts as the mechanical sensor that tells your endothelial cells how fast blood is flowing. This glycocalyx degrades with age, inflammation, and high blood glucose — and until recently, nothing in the supplement space directly addressed rebuilding it.

The research is early but mechanistically coherent. In cell studies, RS has been shown to restore glycocalyx thickness and reduce LDL permeability by nearly threefold in human coronary artery endothelial cells. In ApoE-deficient mice on a high-fat diet, oral RS reduced atherosclerotic plaque area by 36–45% and suppressed vascular inflammation.

Abstract 11489: Oral Rhamnan Sulfate Reduces Vascular Inflammation and Atherosclerotic Plaque Formation | Circulation

A small human case series — six patients with carotid atherosclerotic plaque enrolled in a cardiovascular prevention programme — found that all six showed measurable reductions in total plaque burden over six months, with a mean reduction of 5.55 mm. That study is uncontrolled and has a conflicted author, so it needs to be read carefully, but it is the only published human data I currently have.

No randomised controlled trials in humans have been published as of 2025. That is the honest picture.

If you have been experimenting with RS I would love to hear what you have noticed, what you were measuring (if anything), how long you have been taking it, and what else you were doing at the same time. Anecdote is not evidence, but a community of careful self-experimenters sharing structured observations is where a lot of the most useful signal comes from before the RCTs arrive.